Fulgent Total Current Liabilities vs Cash Analysis

FLGT Stock

USD 17.34 0.38 2.24%

Fulgent Genetics financial indicator trend analysis is much more than just examining Fulgent Genetics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Fulgent Genetics is a good investment. Please check the relationship between Fulgent Genetics Total Current Liabilities and its Cash accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulgent Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.

Total Current Liabilities vs Cash

Total Current Liabilities vs Cash Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Fulgent Genetics Total Current Liabilities account and Cash. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Fulgent Genetics' Total Current Liabilities and Cash is 0.87. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Cash in the same time period over historical financial statements of Fulgent Genetics, assuming nothing else is changed. The correlation between historical values of Fulgent Genetics' Total Current Liabilities and Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Fulgent Genetics are associated (or correlated) with its Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash has no effect on the direction of Total Current Liabilities i.e., Fulgent Genetics' Total Current Liabilities and Cash go up and down completely randomly.

Correlation Coefficient

0.87

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Total Current Liabilities

Total Current Liabilities is an item on Fulgent Genetics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Fulgent Genetics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Cash

Cash refers to the most liquid asset of Fulgent Genetics, which is listed under current asset account on Fulgent Genetics balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Fulgent Genetics customers. The amounts must be unrestricted with restricted cash listed in a different Fulgent Genetics account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Most indicators from Fulgent Genetics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fulgent Genetics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulgent Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.At this time, Fulgent Genetics' Discontinued Operations is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 107.5 M in 2025, whereas Tax Provision is likely to drop slightly above 2.9 M in 2025.

	2022	2023	2024	2025 (projected)
Gross Profit	366.9M	104.5M	120.1M	180.0M
Total Revenue	619.0M	289.2M	332.6M	266.7M

Gross Profit Total Revenue

Fulgent Genetics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Property Plant Equipment	Common Stock Total Equity	Common Stock	Other Liab
Total Assets		0.93	0.84	1.0	0.99	0.98	-0.88	0.98	0.84	0.94	0.9	-0.12	0.35	0.87	0.62	0.92	0.66	0.87	0.98	0.95	0.97	0.87	0.98	-0.61	-0.61	0.85
Other Current Liab	0.93		0.92	0.92	0.94	0.9	-0.9	0.87	0.92	0.94	0.79	-0.1	0.33	0.82	0.83	0.88	0.86	0.72	0.96	0.99	0.87	0.86	0.89	-0.62	-0.62	0.71
Total Current Liabilities	0.84	0.92		0.82	0.84	0.74	-0.88	0.78	1.0	0.87	0.56	-0.27	0.45	0.92	0.89	0.87	0.91	0.63	0.86	0.94	0.71	0.95	0.75	-0.58	-0.58	0.52
Total Stockholder Equity	1.0	0.92	0.82		0.99	0.98	-0.88	0.99	0.83	0.93	0.9	-0.11	0.35	0.86	0.6	0.92	0.64	0.88	0.97	0.94	0.97	0.86	0.98	-0.61	-0.61	0.86
Net Tangible Assets	0.99	0.94	0.84	0.99		0.96	-0.92	0.97	0.84	0.97	0.87	-0.03	0.43	0.88	0.66	0.92	0.69	0.82	0.98	0.95	0.95	0.88	0.96	-0.62	-0.62	0.81
Property Plant And Equipment Net	0.98	0.9	0.74	0.98	0.96		-0.8	0.96	0.75	0.88	0.97	-0.08	0.18	0.75	0.52	0.88	0.56	0.9	0.96	0.91	1.0	0.75	1.0	-0.59	-0.59	0.93
Net Debt	-0.88	-0.9	-0.88	-0.88	-0.92	-0.8		-0.84	-0.86	-0.98	-0.64	-0.15	-0.69	-0.91	-0.81	-0.88	-0.84	-0.56	-0.89	-0.9	-0.77	-0.93	-0.78	0.6	0.6	-0.53
Retained Earnings	0.98	0.87	0.78	0.99	0.97	0.96	-0.84		0.78	0.9	0.9	-0.13	0.34	0.86	0.51	0.88	0.56	0.9	0.93	0.89	0.97	0.84	0.97	-0.51	-0.51	0.87
Accounts Payable	0.84	0.92	1.0	0.83	0.84	0.75	-0.86	0.78		0.86	0.58	-0.29	0.39	0.91	0.89	0.88	0.9	0.65	0.87	0.94	0.72	0.94	0.76	-0.62	-0.62	0.55
Cash	0.94	0.94	0.87	0.93	0.97	0.88	-0.98	0.9	0.86		0.75	0.11	0.59	0.89	0.78	0.89	0.81	0.66	0.94	0.94	0.85	0.91	0.86	-0.61	-0.61	0.64
Non Current Assets Total	0.9	0.79	0.56	0.9	0.87	0.97	-0.64	0.9	0.58	0.75		-0.06	0.0	0.57	0.32	0.77	0.37	0.89	0.86	0.78	0.98	0.57	0.96	-0.49	-0.49	0.97
Non Currrent Assets Other	-0.12	-0.1	-0.27	-0.11	-0.03	-0.08	-0.15	-0.13	-0.29	0.11	-0.06		0.45	-0.2	-0.02	-0.13	0.01	-0.45	-0.09	-0.17	-0.11	-0.17	-0.15	0.12	0.12	-0.25
Other Assets	0.35	0.33	0.45	0.35	0.43	0.18	-0.69	0.34	0.39	0.59	0.0	0.45		0.63	0.51	0.39	0.52	-0.04	0.33	0.34	0.16	0.62	0.17	-0.22	-0.22	-0.13
Cash And Short Term Investments	0.87	0.82	0.92	0.86	0.88	0.75	-0.91	0.86	0.91	0.89	0.57	-0.2	0.63		0.73	0.89	0.75	0.68	0.84	0.87	0.74	0.99	0.76	-0.58	-0.58	0.54
Net Receivables	0.62	0.83	0.89	0.6	0.66	0.52	-0.81	0.51	0.89	0.78	0.32	-0.02	0.51	0.73		0.65	1.0	0.28	0.7	0.82	0.46	0.79	0.5	-0.5	-0.5	0.21
Common Stock Shares Outstanding	0.92	0.88	0.87	0.92	0.92	0.88	-0.88	0.88	0.88	0.89	0.77	-0.13	0.39	0.89	0.65		0.69	0.77	0.94	0.89	0.87	0.9	0.88	-0.76	-0.76	0.73
Inventory	0.66	0.86	0.91	0.64	0.69	0.56	-0.84	0.56	0.9	0.81	0.37	0.01	0.52	0.75	1.0	0.69		0.31	0.73	0.84	0.51	0.81	0.54	-0.5	-0.5	0.26
Other Current Assets	0.87	0.72	0.63	0.88	0.82	0.9	-0.56	0.9	0.65	0.66	0.89	-0.45	-0.04	0.68	0.28	0.77	0.31		0.81	0.77	0.92	0.65	0.93	-0.49	-0.49	0.95
Other Stockholder Equity	0.98	0.96	0.86	0.97	0.98	0.96	-0.89	0.93	0.87	0.94	0.86	-0.09	0.33	0.84	0.7	0.94	0.73	0.81		0.96	0.94	0.86	0.95	-0.74	-0.74	0.8
Total Liab	0.95	0.99	0.94	0.94	0.95	0.91	-0.9	0.89	0.94	0.94	0.78	-0.17	0.34	0.87	0.82	0.89	0.84	0.77	0.96		0.88	0.89	0.9	-0.62	-0.62	0.73
Property Plant And Equipment Gross	0.97	0.87	0.71	0.97	0.95	1.0	-0.77	0.97	0.72	0.85	0.98	-0.11	0.16	0.74	0.46	0.87	0.51	0.92	0.94	0.88		0.73	1.0	-0.57	-0.57	0.95
Total Current Assets	0.87	0.86	0.95	0.86	0.88	0.75	-0.93	0.84	0.94	0.91	0.57	-0.17	0.62	0.99	0.79	0.9	0.81	0.65	0.86	0.89	0.73		0.76	-0.59	-0.59	0.53
Property Plant Equipment	0.98	0.89	0.75	0.98	0.96	1.0	-0.78	0.97	0.76	0.86	0.96	-0.15	0.17	0.76	0.5	0.88	0.54	0.93	0.95	0.9	1.0	0.76		-0.59	-0.59	0.94
Common Stock Total Equity	-0.61	-0.62	-0.58	-0.61	-0.62	-0.59	0.6	-0.51	-0.62	-0.61	-0.49	0.12	-0.22	-0.58	-0.5	-0.76	-0.5	-0.49	-0.74	-0.62	-0.57	-0.59	-0.59		1.0	-0.45
Common Stock	-0.61	-0.62	-0.58	-0.61	-0.62	-0.59	0.6	-0.51	-0.62	-0.61	-0.49	0.12	-0.22	-0.58	-0.5	-0.76	-0.5	-0.49	-0.74	-0.62	-0.57	-0.59	-0.59	1.0		-0.45
Other Liab	0.85	0.71	0.52	0.86	0.81	0.93	-0.53	0.87	0.55	0.64	0.97	-0.25	-0.13	0.54	0.21	0.73	0.26	0.95	0.8	0.73	0.95	0.53	0.94	-0.45	-0.45

Click cells to compare fundamentals

Fulgent Genetics Account Relationship Matchups

Fulgent Genetics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	700.5M	1.3B	1.4B	1.2B	1.4B	1.5B
Other Current Liab	35.0M	28.4M	24.2M	26.9M	31.0M	32.5M
Total Current Liabilities	131.1M	112.8M	116.2M	73.0M	84.0M	49.4M
Total Stockholder Equity	569.4M	1.2B	1.3B	1.1B	1.3B	1.4B
Net Tangible Assets	82.8M	569.4M	1.2B	973.0M	1.1B	1.2B
Property Plant And Equipment Net	40.2M	62.3M	81.4M	95.6M	110.0M	115.5M
Net Debt	(71.6M)	(143.6M)	(58.9M)	(82.2M)	(74.0M)	(70.3M)
Retained Earnings	150.9M	657.6M	801M	633.2M	728.2M	764.6M
Accounts Payable	26.5M	20.5M	23.1M	15.4M	17.7M	10.3M
Cash	87.4M	164.9M	79.5M	97.5M	112.1M	117.7M
Non Current Assets Total	84.7M	204.3M	480.4M	727.5M	836.6M	878.4M
Non Currrent Assets Other	(88.0M)	142.0M	(287.4M)	22.7M	20.5M	21.5M
Other Assets	44.5M	912.6M	26.6M	1.0	1.15	1.09
Cash And Short Term Investments	431.9M	935.5M	852.9M	424.2M	487.8M	312.5M
Net Receivables	204.1M	143.3M	52.7M	57.4M	66.1M	52.9M
Common Stock Shares Outstanding	24.1M	31.0M	31.0M	29.8M	34.3M	23.5M
Liabilities And Stockholders Equity	700.5M	1.3B	1.4B	1.2B	1.4B	1.5B
Inventory	16.5M	12.2M	4.3M	5.8M	6.7M	4.4M
Other Current Assets	3.7M	6.0M	44.5M	26.2M	30.2M	31.7M
Other Stockholder Equity	418.1M	501.9M	486.6M	501.7M	577.0M	605.8M
Total Liab	131.1M	112.8M	116.2M	102.0M	117.3M	123.2M
Property Plant And Equipment Gross	41.0M	81.9M	124.6M	135.1M	155.4M	163.1M
Total Current Assets	615.7M	1.1B	905.6M	507.8M	584.0M	365.6M
Accumulated Other Comprehensive Income	438K	(759K)	(20.9M)	1.2M	1.1M	1.1M
Property Plant Equipment	8.6M	40.2M	62.3M	98.9M	113.8M	119.4M
Retained Earnings Total Equity	(63.0M)	(63.4M)	150.9M	657.6M	756.2M	794.0M
Short Term Investments	344.4M	770.7M	773.4M	326.7M	375.7M	326.9M
Non Current Liabilities Total	959K	7.5M	28.1M	29.0M	33.4M	35.0M
Capital Surpluse	114.2M	146.1M	418.1M	501.9M	577.2M	606.1M
Long Term Investments	132.5M	507.0M	339.0M	444.0M	510.6M	536.1M
Non Current Liabilities Other	959K	7.5M	28.1M	11.0M	12.6M	6.8M
Net Invested Capital	584.4M	1.2B	1.3B	1.1B	1.3B	688.3M
Net Working Capital	393.5M	961.6M	539.8M	434.8M	500.1M	381.8M
Short Long Term Debt Total	15.9M	21.3M	20.6M	15.3M	17.5M	16.7M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Fulgent Stock Analysis

When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC